# CMS Manual System <br> Pub 100-04 Medicare Claims Processing 

## Department of Health \& <br> Human Services (DHHS)

Centers for Medicare \&
Medicaid Services (CMS)
Transmittal 1669
Date: January 13, 2009
Change Request 6323

## SUBJECT: January 2009 Update of the Ambulatory Surgical Center (ASC) Payment System

I. SUMMARY OF CHANGES: This Recurring Update Notification describes changes to and billing instructions for various payment policies implemented in the January 2009 ASC update. As appropriate, this notification also includes updates to the Healthcare Common Procedure Coding System (HCPCS). This recurring update applies to Pub. 100-04, chapter 14, sections 10.2 and 40.8

NEW / REVISED MATERIAL
EFFECTIVE DATE: *January 1, 2009
IMPLEMENTATION DATE: January 5, 2009

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.
II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated)

R=REVISED, $\mathrm{N}=\mathrm{NEW}, \mathrm{D}=\mathrm{DELETED}-$ Only One Per Row.

| R/N/D | Chapter / Section / Subsection / Title |
| :--- | :--- |
| R | 14/40/40.8/Payment When a Device is Furnished With No Cost or With Full or <br> Partial Credit Beginning January 1, 2008 |

## III. FUNDING:

SECTION A: For Fiscal Intermediaries and Carriers:
No additional funding will be provided by CMS; Contractor activities are to be carried out within their operating budgets.

SECTION B: For Medicare Administrative Contractors (MACs):
The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

## IV. ATTACHMENTS:

Manual Instruction
Recurring Update Notification
*Unless otherwise specified, the effective date is the date of service.

# Attachment - Recurring Update Notification 

| Pub. 100-04 | Transmittal: 1669 | Date: January 13, 2009 | Change Request: 6323 |
| :--- | :--- | :--- | :--- |

SUBJECT: January 2009 Update of the Ambulatory Surgical Center (ASC) Payment System
EFFECTIVE DATE: January 1, 2009
IMPLEMENTATION DATE: January 5, 2009

## I. GENERAL INFORMATION

## A. Background:

This Recurring Update Notification describes changes to and billing instructions for various payment policies implemented in the January 2009 ASC update. As appropriate, this notification also includes updates to the Healthcare Common Procedure Coding System (HCPCS).

Included in this notification are updated payment rates for selected separately payable drugs and biologicals, long descriptors for newly created Level II HCPCS codes for drugs and biologicals (ASC DRUG files), and the CY 2009 ASC payment rates for covered surgical and ancillary services (ASCFS file).

## B. Policy:

## a. Updated Core Based Statistical Areas (CBSA)

Table 1 below shows updates to four CBSAs recognized by CMS for ASC claims with dates of service on and after January 1, 2009. Contractor systems should be updated to reflect the CY 2009 CBSA as displayed in Table 1.

Table 1- January 1, 2009 Core Based Statistical Area (CBSA) Changes

| COUNTY/STATE | FIPS CODE | 2008 CBSA | 2009 CBSA |
| :--- | :--- | :--- | :---: |
| Sarasota, Florida | 12115 | 42260 | 14600 |
| Chautauqua, New York | 36013 | 27460 | 33 |
| Garfield, Oklahoma | 40047 | 21420 | 37 |
| Stanly, North Carolina | 37167 | 34 | 16740 |

## b. Drugs and Biologicals with Payment Based on Average Sales Price (ASP) Effective January 1, 2009

In the CY 2009 OPPS/ASC final rule with comment period, it was stated that payments for separately payable drugs and biologicals based on the average sales prices (ASPs) will be updated on a quarterly basis as later quarter ASP submissions become available. Effective January 1, 2009, payment rates for many covered ancillary drugs and biologicals have changed from the values published in the CY 2009 OPPS/ASC final rule with comment period as a result of the new ASP calculations based on sales price submissions from the third quarter of CY 2008. In cases where adjustments to payment rates are necessary, the updated
payment rates will be incorporated in the January 2009 release of the ASC DRUG file. CMS is not publishing the updated payment rates in this Change Request implementing the January 2009 update of the ASC payment system. However, the updated payment rates effective January 1, 2009 for covered ancillary drugs and biologicals can be found in the January 2009 update of the ASC Addendum BB on the CMS Web site.

## c. New HCPCS Codes for Drugs and Biologicals that are Separately Payable under the ASC Payment System as of January 1, 2009

For CY 2009, new Level II HCPCS codes have been created for reporting specific drugs and biologicals for which no previous payable HCPCS code existed. Thirty of the new Level II HCPCS codes for reporting drugs and biologicals are separately payable to ASCs for dates of service on or after January 1, 2009. The new Level II HCPCS codes, their payment indicators, and long descriptors are displayed in Table 2 below and are included in the January 2009 ASC DRUG file.

Table 2 - New Level II HCPCS Codes for Drugs and Biologicals Separately Payable under the ASC Payment System for CY 2009

| HCPCS <br> Code | $\begin{gathered} \hline \text { CY } \\ 2009 \\ \text { Payment } \\ \text { Indicator } \end{gathered}$ | Long Descriptor |
| :---: | :---: | :---: |
| C9245 | K2 | Injection, romiplostim, 10 mcg |
| C9246 | K2 | Injection, gadoxetate disodium, per ml |
| C9248 | K2 | Injection, clevidipien butyrate, 1 mg |
| J0641 | K2 | Injection, levoleucovorin calcium, 0.5 mg |
| J1267 | K2 | Injection, doripenem, 10 mg |
| J1453 | K2 | Injection, fosaprepitant, 1 mg |
| J1459 | K2 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g. liquid), 500 mg |
| J1750 | K2 | Injection, iron dextran, 50 mg |
| J1930 | K2 | Injection, lanreotide, 1 mg |
| J1953 | K2 | Injection, levetiracetam, 10 mg |
| J2785 | K2 | Injection, regadenoson, 0.1 mg |
| J3101 | K2 | Injection, tenecteplase, 1 mg |
| J7186 | K2 | Injection, antihemophilic factor viii/von willebrand factor complex (human), per factor viii i.u. |
| J8705 | K2 | Topotecan, oral, 0.25 mg |
| J9033 | K2 | Injection, bendamustine hcl, 1 mg |
| J9207 | K2 | Injection, ixabepilone, 1 mg |
| J9330 | K2 | Injection, temsirolimus, 1 mg |
| J0132 | K2 | Injection, acetylcysteine, 100 mg |
| J0470 | K2 | Injection, dimercaprol, per 100 mg |
| J0550 | K2 | Injection, penicillin g benzathine and penicillin g procaine, up to 2,400,000 units |
| J0630 | K2 | Injection, calcitonin salmon, up to 400 units |


| J1212 | K2 | Injection, dmso, dimethyl sulfoxide, 50\%, 50 ml |
| :---: | :---: | :---: |
| J1455 | K2 | Injection, foscarnet sodium, per 1000 mg |
| J2460 | K2 | Injection, oxytetracycline hcl, up to 50 mg |
| J2515 | K2 | Injection, pentobarbital sodium, per 50 mg |
| J2805 | K2 | Injection, sincalide, 5 micrograms |
| J3400 | K2 | Injection, triflupromazine hcl, up to 20 mg |
| J7191 | K2 | Factor viii (antihemophilic factor (porcine)), per i.u. |
| J7516 | K2 | Cyclosporin, parenteral, 250 mg |
| J9165 | K2 | Injection, diethylstilbestrol diphosphate, 250 mg |
| 90296 | K2 | Diphtheria antitoxin, equine, any route |
| 90378 | K2 | Respiratory syncytial virus immune globulin (rsv-igim), for intramuscular use, 50 mg , each |
| 90665 | K2 | Lyme disease vaccine, adult sodate, for intramuscular use |
| 90681 | K2 | Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use |
| 90696 | K2 | Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use |
| 90740 | F4 | Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (3 dose schedule), for intramuscular use |
| 90743 | F4 | Hepatitis B vaccine, adolescent (2 dose schedule), for intramuscular use |
| 90744 | F4 | Hepatitis B vaccine, pediatric/adolescent dosage (3 dose schedule), for intramuscular use |
| 90746 | F4 | Hepatitis B vaccine, adult dosage, for intramuscular use |
| 90747 | F4 | Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose schedule), for intramuscular use |
| Q4101 | K2 | Skin substitute, apligraf, per square centimeter |
| Q4102 | K2 | Skin substitute, oasis wound matrix, per square centimeter |
| Q4103 | K2 | Skin substitute, oasis burn matrix, per square centimeter |
| Q4104 | K2 | Skin substitute, integra bilayer matrix wound dressing (bmwd), per square centimeter |
| Q4105 | K2 | Skin substitute, integra dermal regeneration template (drt), per square centimeter |
| Q4106 | K2 | Skin substitute, dermagraft, per square centimeter |
| Q4107 | K2 | Skin substitute, graft jacket, per square centimeter |


| Q4108 | K2 | Skin substitute, integra matrix, per square <br> centimeter |
| :--- | :---: | :--- |
| Q4110 | K2 | Skin substitute, primatrix, per square <br> centimeter |
| Q4111 | K2 | Skin substitute, gammagraft, per square <br> centimeter |
| Q4112 | K2 | Allograft, cymetra, injectable, 1cc |
| Q4113 | K2 | Allograft, graft jacket express, injectable, 1cc |
| Q4114 | K2 | Allograft, integra flowable wound matrix, <br> injectable, 1cc |

## d. Updated Payment Rates for Certain HCPCS Codes Effective April 1, 2008

 through June 30, 2008The payment rates for six drugs and biologicals were incorrect in the April 2008 ASC DRUG file. The corrected payment rates are listed below and have been corrected in the revised April 2008 ASC DRUG file. The corrected rates are effective for services furnished on April 1, 2008 through implementation of the July 2008 update.

Table 3-Updated Payment Rates for Certain Drugs and Biologicals Effective April 1, 2008 through June 30, 2008

| HCPCS <br> Code | CY <br> 2008 <br> PI | Short Descriptor | Corrected <br> Payment <br> Rate |
| :---: | :---: | :--- | ---: |
| J0150 | K2 | Injection adenosine 6 <br> MG | $\$ 12.71$ |
| J1626 | K2 | Granisetron HCl <br> injection | $\$ 5.99$ |
| J2405 | K2 | Ondansetron hcl <br> injection | $\$ 0.23$ |
| J2730 | K2 | Pralidoxime chloride inj | $\$ 83.17$ |
| J9208 | K2 | Ifosfomide injection | $\$ 36.77$ |
| J9209 | K2 | Mesna injection | $\$ 7.81$ |

e. Updated Payment Rates for Certain Drugs and Biologicals Effective July 1, 2008 through September 30, 2008

The payment rates for nine drugs and biologicals were incorrect in the July 2008 ASC DRUG file. The corrected payment rates are listed below and have been corrected in the revised July 2008 ASC DRUG file. The corrected rates are effective for services furnished on July 1, 2008 through implementation of the October 2008 update.

Table 4-Updated Payment Rates for Certain Drugs and Biologicals Effective July 1, 2008 through September 30, 2008

| CY <br> 2008 <br> HCPCS <br> Code | CY <br> 2008 <br> PI |  | Short Descriptor |
| :---: | :---: | :--- | ---: |
| J0150 | K2 | Injection adenosine 6 MG | Payment <br> Rate |
| J1566 | K2 | Immune globulin, powder | $\$ 28.37$ |
| J1569 | K2 | Gammagard liquid <br> injection | $\$ 34.66$ |
| J2730 | K2 | Pralidoxime chloride inj | $\$ 84.90$ |
| J7190 | K2 | Factor viii | $\$ 0.85$ |
| J7192 | K2 | Factor viii recombinant | $\$ 1.12$ |
| J7198 | K2 | Anti-inhibitor | $\$ 1.47$ |
| J8510 | K2 | Oral busulfan | $\$ 2.55$ |
| J9208 | K2 | Ifosfomide injection | $\$ 34.04$ |

f. Updated Payment Rates for Certain Drugs and Biologicals Effective October 1, 2008 through December 31, 2008

The payment rates for two drugs and biologicals were incorrect in the October 2008 ASC DRUG file. The corrected payment rates are listed below and have been corrected in the revised October 2008 ASC DRUG file. The corrected rates are effective for services furnished on October 1, 2008 through implementation of the January 2009 update.

Table 5- Updated Payment Rates for Certain Drugs and Biologicals Effective October 1, 2008 through December 31, 2008

| CY <br> $\mathbf{2 0 0 8}$ <br> HCPCS <br> Code | CY <br> C008 |  | Corrected <br> Payment |
| :---: | :---: | :--- | ---: |
| J1568 | K2 | Octagam injection | $\$ 35.58$ |
|  |  | Natalizumab <br> Rate |  |
| J2323 | K2 | injection | $\$ 7.51$ |

## g. Correct Reporting of Drugs and Biologicals When Used As Implantable Devices

When billing for a biological for which the HCPCS code describes a product that is solely surgically implanted or inserted, and that is separately payable under the ASC payment system, the ASC should report the HCPCS code for the product. If the implanted biological is packaged, that is, not eligible for separate payment under the ASC payment system, the ASC should not report the biological product HCPCS code.

When billing for a biological for which the HCPCS code describes a product that may be either surgically implanted or inserted or otherwise applied in the care of a patient, ASCs should not report the HCPCS code for the product when the biological is used as an implantable device (including as a scaffold or an alternative to human or nonhuman connective tissue or mesh used in a graft) during surgical procedures. Under the ASC payment system, ASCs are provided a packaged payment for surgical procedures that includes the cost of supportive items. When using biologicals during surgical procedures as implantable devices, ASCs may include the charges for these items in their charge for the procedure.

## h. Correct Reporting of Units for Drugs

ASCs are reminded to ensure that units of drugs administered to patients are accurately reported in terms of the dosage specified in the HCPCS long code descriptor. That is, units should be reported in multiples of the units included in the HCPCS descriptor. For example, if the description for the drug code is 6 mg , and 6 mg of the drug was administered to the patient, the units billed should be 1 . As another example, if the description for the drug code is 50 mg , but 200 mg of the drug was administered to the patient, the units billed should be 4. ASCs should not bill the units based on the way the drug is packaged, stored, or stocked. That is, if the HCPCS descriptor for the drug code specifies 1 mg and a 10 mg vial of the drug was administered to the patient, bill 10 units, even though only 1 vial was administered. The HCPCS short descriptors are limited to 28 characters, including spaces, so short descriptors do not always capture the complete description of the drug. Therefore, before submitting Medicare claims for drugs and biologicals, it is extremely important to review the complete long descriptors for the applicable HCPCS codes.

## i. Manual Updates for the No Cost/Full Credit and Partial Credit Device Payment Adjustment Policy

CMS is revising Chapter 4 , section 40.8 to clarify correct coding and charging practices for devices furnished without cost or with a full or partial credit from the manufacturer.

For CY 2009, the list of procedures to which the no cost/full credit and partial credit device adjustment policy applies and the devices to which the policy applies are displayed in Attachments B and C, respectively, to this transmittal. The tables can also be found on the CMS Web site.

## j. Attachments

Several attachments are provided to this transmittal that contractors may wish to use as references to support their ASC module updating and validation processes.

Attachment A: Surgical procedures and ancillary services that are newly payable in the ASC setting effective January 1, 2009.

Attachment B: Procedures to which the no cost/full credit and partial credit device adjustment policy applies.

Attachment C: Devices for which the "FB" or "FC" modifier must be reported with the procedure code when furnished at no cost or with full or partial credit.

## II. BUSINESS REQUIREMENTS TABLE

Use"Shall" to denote a mandatory requirement


| Number | Requirement | Responsibility (place an " $X$ " in each applicable column) |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | A <br> / <br> B <br>  <br> M <br> A <br> A <br> C <br>  <br> P | $\begin{aligned} & \mathrm{D} \\ & \mathrm{M} \\ & \mathrm{E} \\ & \mathrm{M} \\ & \mathrm{~A} \\ & \mathrm{C} \end{aligned}$ | F | C <br> A <br> R <br> R <br> R <br> I <br> E <br> R | $R$ $H$ $H$ I |   <br>   <br>   <br>   <br> I  <br> S  | $\begin{aligned} & \text { Shar } \\ & \text { Syst } \\ & \text { Syinta } \\ & \hline \text { M } \\ & \hline \text { M } \\ & \text { C } \\ & \text { S } \end{aligned}$ | $\begin{aligned} & \text { red- } \\ & \text { tem } \\ & \text { nine } \\ & \text { V } \\ & \mathrm{M} \\ & \mathrm{~S} \end{aligned}$ |  | $\begin{gathered} \text { OTH } \\ \text { ER } \end{gathered}$ |
| 6323.1 | Contractors shall download the January 2009 ASCFS from the CMS mainframe. <br> FILENAME: <br> MU00.@BF12390.ASC.CY09.FS.V1113C <br> Note: The January 2009 ASCFS includes all updates to the CBSA values, list of ASC covered services and services and devices subject to the FB and FC modifier payment adjustment policy as identified in this transmittal. <br> Date of retrieval will be provided in a separate email communication from CMS | X |  |  | X |  |  | X |  |  |  |
| 6323.2 | Contractors shall incorporate updates to the Core Based Statistical Area (CBSA) into ASCFS module programming | X |  |  | X |  |  | X |  |  |  |
| 6323.2.1 | Contractors shall modify their systems to incorporate the CBSA updates for jurisdictional ASCs in Sarasota, FL for dates of service beginning January 1, 2009. <br> From: CBSA 42260 <br> To: CBSA 14600 | X |  |  | X |  |  | X |  |  |  |
| 6323.2.2 | Contractors shall modify their systems to incorporate the CBSA update for jurisdictional ASCs in Chautauqua, NY for dates of service beginning January 1, 2009. <br> From: CBSA 27460 <br> To: CBSA 33 | X |  |  | X |  |  | X |  |  |  |
| 6323.2.3 | Contractors shall modify their systems to incorporate the CBSA update for jurisdictional ASCs in Garfield, OK for dates of service beginning January 1, 2009. <br> From: CBSA 21420 <br> To: CBSA 37 | X |  |  | X |  |  | X |  |  |  |
| 6323.2.4 | Contractors shall modify their systems to incorporate the CBSA update for jurisdictional ASCs in Stanly, NC for dates of service beginning January 1, 2009. <br> From: CBSA 34 <br> To: CBSA 16740 | X |  |  | X |  |  | X |  |  |  |
| 6323.3 | Medicare contractors shall download and install the January 2009 ASC DRUG file | X |  |  | X |  |  | X |  |  |  |

\begin{tabular}{|c|c|c|c|c|c|c|c|c|c|c|c|}
\hline Number \& Requirement \& \multicolumn{10}{|l|}{Responsibility (place an " $X$ " in each applicable column)} <br>
\hline \& \& A
/
B

M
A

C \& $$
\begin{array}{|l|}
\hline \mathrm{D} \\
\mathrm{M} \\
\mathrm{E} \\
\mathrm{M} \\
\mathrm{~A} \\
\mathrm{C}
\end{array}
$$ \& \[

$$
\begin{array}{c|}
\hline \mathrm{F} \\
\mathrm{I} \\
\\
\\
\hline
\end{array}
$$

\] \& \[

$$
\begin{array}{|c|}
\hline \mathrm{C} \\
\mathrm{~A} \\
\mathrm{R} \\
\mathrm{R} \\
\mathrm{I} \\
\mathrm{E} \\
\mathrm{R}
\end{array}
$$

\] \&  \& |  |  |
| :---: | :---: |
| Ma |  |
| I |  |
| S |  |
| S |  | \& \[

$$
\begin{aligned}
& \text { Sha } \\
& \text { Sys } \\
& \text { aint } \\
& \hline \text { M } \\
& \text { C } \\
& \text { S }
\end{aligned}
$$

\] \& \[

$$
\begin{aligned}
& \text { red- } \\
& \text { stem } \\
& \text { taine } \\
& \hline \mathrm{V} \\
& \mathrm{M} \\
& \mathrm{~S}
\end{aligned}
$$

\] \& |  |
| :--- |
|  |
|  |
|  |
|  |
| C |
| F | \& \[

$$
\begin{gathered}
\text { OTH } \\
\text { ER }
\end{gathered}
$$
\] <br>

\hline \& | FILENAME: |
| :--- |
| MU00.@BF12390.ASC.CY09.DRUG.JAN.E.V1218 |
| Date of retrieval will be provided in a separate email communication from CMS | \& \& \& \& \& \& \& \& \& \& <br>


\hline 6323.4 \& | Medicare contractors shall download and install a revised April 2008 ASC DRUG file |
| :--- |
| FILENAME: |
| MU00.@BF12390.ASC.CY08.DRUG.APR.E.V1218 |
| Confirmation and date of retrieval will be provided in a separate email communication from CMS | \& X \& \& \& X \& \& \& X \& \& \& <br>


\hline 6323.4.1 \& | Medicare contractors shall adjust as appropriate claims brought to their attention that: |
| :--- |
| 1) Have dates of service on or after April 1, 2008, but prior to July 1, 2008 and ; |
| 2) Were originally processed prior to the installation of the revised April 2008 ASC DRUG File. | \& X \& \& \& X \& \& \& X \& \& \& <br>


\hline 6323.5 \& | Medicare contractors shall download and install a revised July 2008 ASC DRUG file |
| :--- |
| FILENAME: |
| MU00.@BF12390.ASC.CY08.DRUG.JUL.E.V1218 |
| Confirmation and date of retrieval will be provided in a separate email communication from CMS | \& X \& \& \& X \& \& \& X \& \& \& <br>


\hline 6323.5.1 \& | Medicare contractors shall adjust as appropriate claims brought to their attention that: |
| :--- |
| 1) Have dates of service on or after July 1, 2008, but prior to October 1, 2008 and ; |
| 2) Were originally processed prior to the installation of the revised July 2008 ASC DRUG File. | \& X \& \& \& X \& \& \& X \& \& \& <br>

\hline 6323.6 \& Medicare contractors shall download and install a revised October 2008 ASC DRUG file \& X \& \& \& X \& \& \& X \& \& \& <br>
\hline
\end{tabular}

| Number | Requirement | Responsibility (place an " $X$ " in each applicable column) |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | A | $\begin{aligned} & \mathrm{D} \\ & \mathrm{M} \\ & \mathrm{E} \\ & \mathrm{M} \\ & \mathrm{~A} \\ & \mathrm{C} \end{aligned}$ | $\begin{array}{c\|} \hline \mathrm{F} \\ \mathrm{I} \\ \\ \\ \hline \end{array}$ | $\begin{aligned} & \mathrm{C} \\ & \mathrm{~A} \\ & \mathrm{R} \\ & \mathrm{R} \\ & \mathrm{I} \\ & \mathrm{E} \\ & \mathrm{R} \end{aligned}$ | $\begin{array}{\|c\|} \hline \mathrm{R} \\ \mathrm{H} \\ \mathrm{H} \\ \mathrm{I} \end{array}$ |  | Share <br> Syste <br> ainta <br> M <br> C <br> S | $\begin{aligned} & \text { red- } \\ & \text { tem } \\ & \text { aine } \\ & \text { aine } \\ & \hline \mathrm{V} \\ & \mathrm{M} \\ & \mathrm{~S} \end{aligned}$ |   <br>   <br>   <br>   <br>   <br> $F$  | $\begin{gathered} \text { OTH } \\ \text { ER } \end{gathered}$ |
|  | FILENAME: <br> MU00.@BF12390.ASC.CY08.DRUG.OCT.E.V1218 <br> Confirmation and date of retrieval will be provided in a separate email communication from CMS |  |  |  |  |  |  |  |  |  |  |
| 6323.6.1 | Medicare contractors shall adjust as appropriate claims brought to their attention that: <br> 1) Have dates of service on or after October 1, 2008, but prior to January 1, 2009 and ; 2) Were originally processed prior to the installation of the revised October 2008 ASC DRUG File. | X |  |  | X |  |  | X |  |  |  |
| 6323.7 | Contractors and CWF shall manually update the HCPCS file to reflect an ASC payment group value "YY" for HCPCS 28011. | X |  |  | X |  |  |  |  | X |  |

## III. PROVIDER EDUCATION TABLE



## IV. SUPPORTING INFORMATION

Section A: For any recommendations and supporting information associated with listed requirements, use the box below:

| X-Ref <br> Requireme <br> nt <br> Number | Recommendations or other supporting information: |
| :--- | :--- |
|  | $\mathrm{n} / \mathrm{a}$ |

Section B: For all other recommendations and supporting information, use this space:

## V. CONTACTS

Pre-Implementation Contact(s): ASC Payment Policy: Chuck Braver at chuck.braver@cms.hhs.gov or 410-786-6719;. Carrier/ AB MAC Claims Processing Issues: Yvette Cousar at yvette.cousar@cms.hhs.gov or 410-786-2160.

Post-Implementation Contact(s): ASC Payment Policy: Chuck Braver at chuck.braver@cms.hhs.gov or 410-786-6719;. Carrier/ AB MAC Claims Processing Issues: Yvette Cousar at yvette.cousar@cms.hhs.gov or 410-786-2160.

## VI. FUNDING

## Section A: For Carriers:

No additional funding will be provided by CMS; contractor activities are to be carried out within their operating budgets.

## Section B: For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

Attachments

ASC Covered Surgical Procedures and Ancillary Services Added For CY 2009

|  |  |
| :---: | :--- |
| HCPCS <br> Code | Short Descriptor |
| 0190 T | Place intraoc radiation src |
| 0191 T | Insert ant segment drain int |
| 0192 T | Insert ant segment drain ext |
| 15170 | Acell graft trunk/arms/legs |
| 15171 | Acell graft t/arm/leg add-on |
| 15175 | Acellular graft, f/n/hf/g |
| 15176 | Acell graft, f/n/hf/g add-on |
| 20696 | Comp multiplane ext fixation |
| 20697 | Comp ext fixate strut change |
| 34490 | Removal of vein clot |
| 36455 | Bl exchange/transfuse non-nb |
| 41530 | Tongue base vol reduction |
| 43273 | Endoscopic pancreatoscopy |
| $46930^{*}$ | Destroy internal hemorrhoids |
| 49324 | Lap insertion perm ip cath |
| 49325 | Lap revision perm ip cath |
| 49326 | Lap w/omentopexy add-on |
| 49652 | Lap vent/abd hernia repair |
| 49653 | Lap vent/abd hern proc comp |
| 49654 | Lap inc hernia repair |
| 49655 | Lap inc hern repair comp |
| 49656 | Lap inc hernia repair recur |
| 49657 | Lap inc hern recur comp |
| 55706 | Prostate saturation sampling |
| 62267 | Interdiscal perq aspir, dx |
| 64448 | N block inj fem, cont inf |
| 64449 | N block inj, lumbar plexus |
| $64455^{*}$ | N block inj, plantar digit |
| $64632 *$ | N block inj, common digit |
| 65756 | Corneal trnspl, endothelial |
| 77785 | Hdr brachytx, 1 channel |
| 77786 | Hdr brachytx, 2-12 channel |
| 77787 | Hdr brachytx over 12 chan |
|  |  |

CY 2009 ASC Covered Surgical Procedures to Which the No Cost/Full Credit and Partial Credit Device Adjustment Policy Applies

| HCPCS Code | Short Descriptor |
| :---: | :---: |
| 24361 | Reconstruct elbow joint |
| 24363 | Replace elbow joint |
| 24366 | Reconstruct head of radius |
| 25441 | Reconstruct wrist joint |
| 25442 | Reconstruct wrist joint |
| 25446 | Wrist replacement |
| 27446 | Revision of knee joint |
| 33206 | Insertion of heart pacemaker |
| 33207 | Insertion of heart pacemaker |
| 33208 | Insertion of heart pacemaker |
| 33212 | Insertion of pulse generator |
| 33213 | Insertion of pulse generator |
| 33214 | Upgrade of pacemaker system |
| 33224 | Insert pacing lead \& connect |
| 33225 | L ventric pacing lead addon |
| 33240 | Insert pulse generator |
| 33249 | Eltrd/insert pace-defib |
| 33282 | Implant pat-active ht record |
| 53440 | Male sling procedure |
| 53444 | Insert tandem cuff |
| 53445 | Insert uro/ves nck sphincter |
| 53447 | Remove/replace ur sphincter |
| 54400 | Insert semi-rigid prosthesis |
| 54401 | Insert self-contd prosthesis |
| 54405 | Insert multi-comp penis pros |
| 54410 | Remove/replace penis prosth |
| 54416 | Remv/repl penis contain |


|  | pros |
| :---: | :--- |
| 55873 | Cryoablate prostate |
| 61885 | Insrt/redo neurostim 1 array |
| 61886 | Implant neurostim arrays |
| 62361 | Implant spine infusion <br> pump |
| 62362 | Implant spine infusion <br> pump |
| 63650 | Implant neuroelectrodes |
| 63655 | Implant neuroelectrodes |
| 63685 | Insrt/redo spine n generator |
| 64553 | Implant neuroelectrodes |
| 64555 | Implant neuroelectrodes |
| 64560 | Implant neuroelectrodes |
| 64561 | Implant neuroelectrodes |
| 64565 | Implant neuroelectrodes |
| 64573 | Implant neuroelectrodes |
| 64575 | Implant neuroelectrodes |
| 64577 | Implant neuroelectrodes |
| 64580 | Implant neuroelectrodes |
| 64581 | Implant neuroelectrodes |
| 64590 | Insrt/redo pn/gastr stimul |
| 65770 | Revise cornea with implant |
| 69714 | Implant temple bone <br> w/stimul |
| 69715 | Temple bne implnt <br> w/stimulat |
| 69717 | Temple bone implant <br> revision |
| 69718 | Revise temple bone implant |
| 69930 | Implant cochlear device |

CY 2009 Devices for Which Modifier "FB" or "FC" Must be Reported with the Procedure Code When Furnished at No Cost or With Full or Partial Credit

| Device <br> HCPCS <br> Code | Short Descriptor |
| :---: | :--- |
| C1721 | AICD, dual chamber |
| C1722 | AICD, single chamber |
| C1764 | Event recorder, cardiac |
| C1767 | Generator, neurostim, imp |
| C1771 | Rep dev, urinary, w/sling |
| C1772 | Infusion pump, programmable |
| C1776 | Joint device (implantable) |
| C1778 | Lead, neurostimulator |
| C1779 | Lead, pmkr, transvenous VDD |
| C1785 | Pmkr, dual, rate-resp |
| C1786 | Pmkr, single, rate-resp |
| C1813 | Prosthesis, penile, inflatab |
| C1815 | Pros, urinary sph, imp |
| C1820 | Generator, neuro rechg bat sys |
| C1881 | Dialysis access system |


| Device <br> HCPCS <br> Code | Short Descriptor |
| :---: | :--- |
| C1882 | AICD, other than sing/dual |
| C1891 | Infusion pump, non-prog, perm |
| C1897 | Lead, neurostim, test kit |
| C1898 | Lead, pmkr, other than trans |
| C1900 | Lead coronary venous |
| C2619 | Pmkr, dual, non rate-resp |
| C2620 | Pmkr, single, non rate-resp |
| C2621 | Pmkr, other than sing/dual |
| C2622 | Prosthesis, penile, non-inf |
| C2626 | Infusion pump, non-prog, temp |
| C2631 | Rep dev, urinary, w/o sling |
| L8614 | Cochlear device/system |
| L8690 | Aud osseo dev, int/ext comp |

## 40.8 - Payment When a Device is Furnished With No Cost or With Full or Partial Credit Beginning January 1, 2008

(Rev.1669, Issued: 01-13-09, Effective: 01-01-09, Implementation: 01-05-09)
Contractors pay ASCs a reduced amount for certain specified procedures when a specified device is furnished without cost or for which either a partial or full credit is received (e.g., device recall). For specified procedure codes that include payment for a device, ASCs are required to include modifier $-F B$ on the procedure code when a specified device is furnished without cost or for which full credit is received. If the ASC receives a partial credit of 50 percent or more of the cost of $a$ specified device, the ASC is required to include modifier $-F C$ on the procedure code if the procedure is on the list of specified procedures to which the -FC reduction applies. A single procedure code should not be submitted with both modifiers $-F B$ and $-F C$. The pricing determination related to modifiers $-F B$ and $-F C$ is made prior to the application of multiple procedure payment reductions. Contractors adjust beneficiary coinsurance to reflect the reduced payment amount. Tables listing the procedures and devices to which the payment adjustments apply, and the full and partial adjustment amounts, are available on the CMS Web site.

In order to report that the receipt of a partial credit of 50 percent or more of the cost of a device, ASCs have the option of either: 1) Submitting the claim for the procedure to their Medicare contractor after the procedure's performance but prior to manufacturer acknowledgement of credit for a specified device, and subsequently contacting the contractor regarding a claims adjustment once the credit determination is made; or 2) holding the claim for the procedure until a determination is made by the manufacturer on the partial credit and submitting the claim with modifier -FC appended to the implantation procedure HCPCS code if the partial credit is 50 percent or more of the cost of the device. If choosing the first billing option, to request a claims adjustment once the credit determination is made, ASCs should keep in mind that the initial Medicare payment for the procedure involving the device is conditional and subject to adjustment.

